Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Breastfeeding supports healthy infant microbiome, lowering asthma risk
Breastfeeding through the first year of infants' lives can lower their risk of asthma by colonizing their bodies with a ...
US ranks last in health care compared with nine other high-income countries, report finds
People in the U.S. die the youngest and experience the most avoidable deaths, despite spending much more on health care.
Medscape13h
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
Black women are more likely than white women to die of all types of breast cancer
Black women are more likely than white women to die from even the most treatable types of breast cancer, a study published ...
scrippsnews1d
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
BlackDoctor1d
This Early-Stage Breast Cancer Drug Will Be Widely Available, Thanks to a Clinical Trial
The FDA has expanded its approval of Kisqali, a drug already approved to treat advanced breast cancer, to include women with ...
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
BioPharma Dive1d
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
Targeted Oncology1d
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...